BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31466070)

  • 21. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer.
    Yu HJ; Lai MK
    Urology; 1998 May; 51(5A Suppl):125-30. PubMed ID: 9610567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density.
    Schatteman PH; Hoekx L; Wyndaele JJ; Jeuris W; Van Marck E
    Eur Urol; 2000 Apr; 37(4):404-12. PubMed ID: 10765070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of the transition zone index for identification of prostate cancer in Chinese men with intermediate PSA levels.
    Qi TY; Chen YQ; Jiang J; Zhu YK; Yao XH; Wang XJ
    Int Urol Nephrol; 2012 Jun; 44(3):807-15. PubMed ID: 22311386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
    Bare R; Hart L; McCullough DL
    Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guérin vaccine therapy in patients with nonmuscle invasive bladder cancer.
    Wang Z; Han C; Xu Y; Yu X; Kang W; Xiang Y; Yuan Y; Li L; Wang M
    J Cancer Res Ther; 2021 Jul; 17(3):625-629. PubMed ID: 34269291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol.
    Nicolaiew N; Ploussard G; Chun FK; Xylinas E; Allory Y; Salomon L; de la Taille A
    Urol Int; 2013; 90(3):306-11. PubMed ID: 23295308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
    Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
    Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
    Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
    Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chances of subsequent cancer detection in patients with a PSA > 20 ng/ml and an initial negative biopsy.
    Shaida N; Jones CM; Ravindranath N; Malone PR
    ScientificWorldJournal; 2009 May; 9():343-8. PubMed ID: 19468655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prospective validation of a nomogram predictive of a positive initial prostate biopsy].
    Ramírez-Backhaus M; Bahilo P; Arlandis S; Santamaría Navarro C; Pontones Moreno JL; Jiménez-Cruz F
    Actas Urol Esp; 2010 Jan; 34(1):35-42. PubMed ID: 20223131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.
    Zhao R; Huang Y; Cheng G; Liu J; Shao P; Qin C; Hua L; Yin C
    PLoS One; 2014; 9(9):e106933. PubMed ID: 25268808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A long follow-up on prostate specific antigen density and prostate biopsy.
    Netto Júnior NR; De Lima ML; Lavoura Júnior Nda S; Apuzzo F; De Lucena RG
    Arch Esp Urol; 1998 Dec; 51(10):1050-3. PubMed ID: 9951132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
    Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
    Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.